Expert Opinion on Diabetes Management Challenges and Role of Basal Insulin/GLP-1 RA Fixed-Ratio Combination in People with Type 2 Diabetes from Indonesia

References

• American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Supplement_1):S14–S31. doi:10.2337/DC20-S002
   Web of Science ®Google Scholar
• Diabetes. Available from: https://www.who.int/health-topics/diabetes#tab=tab_1. Accessed July 25, 2022.
   Google Scholar
• Western pacific members. Available from: https://www.idf.org/our-network/regions-members/western-pacific/members/western-pacific-members/104-indonesia.html. Accessed July 25, 2022.
   Google Scholar
• Dany F, Dewi RM, Tjandrarini DH, et al. Urban-rural distinction of potential determinants for prediabetes in Indonesian population aged ≥15 years: a cross-sectional analysis of Indonesian Basic Health Research 2018 among normoglycemic and prediabetic individuals. BMC Public Health. 2020;20(1):1–9. doi:10.1186/S12889-020-09592-7/PEER-REVIEW
   Web of Science ®Google Scholar
• Yabe D, Seino Y, Fukushima M, Seino S. β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15(6). doi:10.1007/S11892-015-0602-9
   Web of Science ®Google Scholar
• Inaishi J, Saisho Y. Ethnic similarities and differences in the relationship between beta cell mass and diabetes. J Clin Med. 2017;6(12):113. doi:10.3390/JCM6120113
   Web of Science ®Google Scholar
• Yu Pan C, Han P, Liu X, et al. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia). Diabetes Metab Res Rev. 2014;30(8):726–735. doi:10.1002/DMRR.2541
   Web of Science ®Google Scholar
• Lastya A, Saraswati MR, Suastika K. The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus. BMC Res Notes. 2014;7(1). doi:10.1186/1756-0500-7-849
   Google Scholar
• Yabe D, Kuroe A, Lee S, et al. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Investig. 2010;1(1–2):56–59. doi:10.1111/J.2040-1124.2010.00010.X
   PubMed Web of Science ®Google Scholar
• Vollmer K, Hoist JJ, Bailer B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008;57(3):678–687. doi:10.2337/DB07-1124
   PubMed Web of Science ®Google Scholar
• Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig. 2016;7(Suppl 1):102–109. doi:10.1111/JDI.12490
   PubMed Web of Science ®Google Scholar
• Chan JCN, Yeung R, Luk A. The Asian diabetes phenotypes: challenges and opportunities. Diabetes Res Clin Pract. 2014;105(1):135–139. doi:10.1016/J.DIABRES.2014.05.011
   Web of Science ®Google Scholar
• Wang JS, Tu ST, Lee IT, et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev. 2011;27(1):79–84. doi:10.1002/DMRR.1149
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Borch-Johnsen K, Tajima N, Cockram CS, Nakagami T. Cardiovascular risk profile assessment in glucose-intolerant Asian individuals – an evaluation of the World Health Organization two-step strategy: the DECODA Study (Diabetes Epidemiology: collaborative Analysis of Diagnostic Criteria in Asia). Diabetic Med. 2002;19(7):549–557. doi:10.1046/J.1464-5491.2002.00735.X
   Web of Science ®Google Scholar
• DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ. 1998;317(7155):371–375. doi:10.1136/BMJ.317.7155.371
   Google Scholar
• Native Indonesians. Wikipedia. Available from: https://en.wikipedia.org/wiki/Native_Indonesians. Accessed July 25, 2022.
   Google Scholar
• Simbolon D, Siregar A, Talib RA. Physiological factors and physical activity contribute to the incidence of type 2 diabetes mellitus in Indonesia. Kesmas. 2020;15(3):120–127. doi:10.21109/KESMAS.V15I3.3354
   Web of Science ®Google Scholar
• Cho YM. Characteristics of the pathophysiology of type 2 diabetes in Asians. Ann Laparoscopic Endoscopic Surg. 2017;2(2):14. doi:10.21037/3728
   Google Scholar
• Kosiborod M, Gomes MB, Nicolucci A, et al. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol. 2018;17(1). doi:10.1186/S12933-018-0787-8
   Web of Science ®Google Scholar
• Tarigan TJE, Yunir E, Subekti I, Pramono LA, Martina D. Profile and analysis of diabetes chronic complications in Outpatient Diabetes Clinic of Cipto Mangunkusumo Hospital, Jakarta. Med J Indonesia. 2015;24(3):156–162. doi:10.13181/MJI.V24I3.1249
   Google Scholar
• Murti Andayani T, Izham Mohamed Ibrahim M, Asdie AH. Assessing the impact of complications on the direct medical costs of type 2 diabetes mellitus outpatients. 2022.
   Google Scholar
• Arifin B, van Asselt ADI, Setiawan D, Atthobari J, Postma MJ, Cao Q. Diabetes distress in Indonesian patients with type 2 diabetes: a comparison between primary and tertiary care. BMC Health Serv Res. 2019;19(1):773. doi:10.1186/S12913-019-4515-1/TABLES/2
   Web of Science ®Google Scholar
• Indonesian Society of Endocrinology. Practical Guideline of Insulin Therapy in Patients with Diabetes Mellitus 2021.  Available from: https://pbperkeni.or.id/unduhan. Accessed July 25, 2022.
   Google Scholar
• Indonesian Society of Endocrinology. Guideline of Management and Prevention of Type 2 Diabetes Mellitus in Indonesia 2021. Indonesian Society of Endocrinology Publisher 2021.
   Google Scholar
• Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39(11):2026–2035. doi:10.2337/dc16-0917
   PubMed Web of Science ®Google Scholar
• Cai Y, Zeng T, Wen Z, Chen L. Ethnic differences in efficacy and safety of alogliptin: a systematic review and meta-analysis. Diabetes Ther. 2018;9(1):177–191. doi:10.1007/S13300-017-0352-6
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Fleischmann H, Siegmund T, Seufert J. Rationale for timely insulin therapy in type 2 diabetes within the framework of individualised treatment: 2020 update. Diabetes Ther. 2020;11(8):1645–1666. doi:10.1007/S13300-020-00855-5
   Web of Science ®Google Scholar
• Soewondo P, Ferrario A, Tahapary DL. Challenges in diabetes management in Indonesia: a literature review. Global Health. 2013;9(1):1–17. doi:10.1186/1744-8603-9-63/TABLES/5
   Google Scholar
• Ma RCW, Chan JCN. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281(1):64. doi:10.1111/NYAS.12098
   PubMed Web of Science ®Google Scholar
• Cholil AR, Lindarto D, Pemayun TGD, Wisnu W, Kumala P, Puteri HHS. DiabCare Asia 2012: diabetes management, control, and complications in patients with type 2 diabetes in Indonesia. Med J Indonesia. 2019;28(1):47–56. doi:10.13181/MJI.V28I1.2931
   Web of Science ®Google Scholar
• Universitas Indonesia. Current practice in the management of type 2 diabetes in Indonesia: results from the International Diabetes Management Practices Study (IDMPS). Available from: https://scholar.ui.ac.id/en/publications/current-practice-in-The-management-of-type-2-diabetes-in-indonesi. Accessed July 25, 2022.
   Google Scholar
• Zhang F, Tang L, Zhang Y, Lü Q, Tong N. Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials. Sci Rep. 2017;7(1):1–11. doi:10.1038/s41598-017-16018-9
   PubMed Web of Science ®Google Scholar
• Vichayanrat A, Matawaran BJ, Wibudi A, et al. Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: the Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study. J Diabetes. 2013;5(3):309–318. doi:10.1111/1753-0407.12038
   Web of Science ®Google Scholar
• McKinsey. Tackling Indonesia’s diabetes challenge: eight approaches from around the world. Available from: https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/tackling-indonesias-diabetes-challenge-eight-approaches-from-around-The-world. Accessed July 25, 2022.
   Google Scholar
• Soewondo P, Soegondo S, Suastika K, Pranoto A, Soeatmadji DW, Tjokroprawiro A. The DiabCare Asia 2008 study – outcomes on control and complications of type 2 diabetic patients in Indonesia. Med J Indonesia. 2010;19(4):235–244. doi:10.13181/MJI.V19I4.412
   Google Scholar
• Bailey CJ. The current drug treatment landscape for diabetes and perspectives for the future. Clin Pharmacol Ther. 2015;98(2):170–184. doi:10.1002/CPT.144
   PubMed Web of Science ®Google Scholar
• Hinnen D, Strong J. iGlarLixi: a new once-daily fixed-ratio combination of basal insulin glargine and lixisenatide for the management of type 2 diabetes. Diabetes Spectr. 2018;31(2):145–154. doi:10.2337/DS17-0014
   Google Scholar
• Niemoeller E, Souhami E, Wu Y, Jensen KH. iGlarLixi reduces glycated hemoglobin to a greater extent than basal insulin regardless of levels at screening: post hoc analysis of LixiLan-L. Diabetes Ther. 2018;9(1):373–382. doi:10.1007/S13300-017-0336-6
   PubMed Web of Science ®Google Scholar
• Haluzík M, Flekač M, Lengyel C, et al. Expert opinion on the therapeutic use of the fixed-ratio combination of insulin glargine 100 U/mL and Lixisenatide: a Central/Eastern European perspective. Diabetes Ther. 2020;11(4):1029–1043. doi:10.1007/S13300-020-00777-2
   Web of Science ®Google Scholar
• Peng XV, McCrimmon RJ, Shepherd L, et al. Glycemic control following GLP-1 RA or basal insulin initiation in real-world practice: a retrospective, observational, longitudinal cohort study. Diabetes Ther. 2020;11(11):2629–2645. doi:10.1007/S13300-020-00905-Y
   PubMed Web of Science ®Google Scholar
• Morea N, Retnakaran R, Vidal J, et al. iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: a post hoc analysis from the LixiLan‐L study. Diabetes Obes Metab. 2020;22(9):1683. doi:10.1111/DOM.14077
   Web of Science ®Google Scholar
• Hassanein M, Sahay RK, Malek R, et al. Real-world safety and effectiveness of iGlarLixi in people with type 2 diabetes who fast during ramadan: results from wave 1 of the SOLIRAM study. J Endocr Soc. 2021;5(Suppl 1):A334. doi:10.1210/JENDSO/BVAB048.681
   Google Scholar
• Blonde L, Rosenstock J, Del Prato S, et al. Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the lixilan-G randomized clinical trial. Diabetes Care. 2019;42(11):2108–2116. doi:10.2337/DC19-1357
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/nejmoa1603827
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111–S124. doi:10.2337/DC21-S009
   PubMed Web of Science ®Google Scholar
• Skolnik N, Del Prato S, Blonde L, Galstyan G, Rosenstock J. Translating iGlarLixi evidence for the management of frequent clinical scenarios in type 2 diabetes. Adv Ther. 2021;38(4):1715. doi:10.1007/S12325-020-01614-5
   PubMed Web of Science ®Google Scholar
• PDB39 evaluation of the long-term clinical and economic impact of a 1% HbA1C reduction in patients with type 2 diabetes in Indonesia. Available from: https://www.infona.pl/resource/bwmeta1.element.elsevier-c3d25540-6dea-39b7-9f9d-5566c449a697. Accessed July 25, 2022.
   Google Scholar
• Fda. SOLIQUA 100/33 (insulin glargine and lixisenatide injection); 2022. Available from: www.fda.gov/medwatch. Accessed July 25, 2022.
   Google Scholar